Medical aesthetic company Amedica has officially launched polynucleotide brand Ameela in the UK, after rebranding from Nucleadyn.
At an exclusive press event held at The Twenty Two in London, Ameela revealed clinical data and case studies following the use of the brand’s three polynucleotide products.
The company’s polynucleotides are formed with fragments of salmon DNA, which is similar to humans. These fragments react with patients’ cell receptors when injected, stimulating collagen and elastin production, according to Ameela.
Ameela Eyes, Ameela Rejuvenation and Ameela Face contain differing concentrations of polynucleotides to allow for treatment of both the face and body, Ameela says. At the event, Amedica founder Linn Larsen highlighted the product’s ability to rejuvenate the undereye area, brightening dark circles by boosting hydration and deep tissue stimulation.
Larsen shared that polynucleotides could reduce the need for patients to undergo so many dermal filler treatments, as she said they can stimulate the tissue to rejuvenate without the need for as much volume to be added.
Larsen shared, “Amedica is delighted to have launched Ameela into the UK market. With over four years working with innovative product launches into the global aesthetic market, we are excited at the speed at which practitioners are launching Ameela into their clinical practices. The Ameela portfolio is quickly becoming an essential and vital tool in the practitioner tool kit.”
